Side-by-side comparison of AI visibility scores, market position, and capabilities
AI clinical decision support platform with 59K+ clinician users for differential diagnosis and treatment planning; Initialized Capital-backed competing with UpToDate for physician AI reference.
Glass Health is a clinical decision support platform that uses AI to assist physicians and clinicians in generating differential diagnoses, treatment plans, and clinical assessments — providing a fast-moving AI workspace where clinicians input patient findings (symptoms, vitals, lab results, history) and receive structured clinical reasoning including possible diagnoses ranked by likelihood, recommended workup steps, and evidence-based treatment options. Founded in 2021 in San Francisco and a Y Combinator W23 graduate, Glass Health raised $5 million in seed funding led by Initialized Capital in January 2024, growing to 59,000+ users with notable healthcare founders including Tom Lee (One Medical) and Epocrates team members as backers.\n\nGlass Health's design is built for the clinical workflow — clinicians can quickly enter a patient presentation in natural language and get back a structured differential and workup plan in seconds, useful for initial patient evaluation, complex cases, and educational reference. The platform is designed to augment clinical reasoning rather than replace it, presenting options for clinician evaluation rather than prescribing a single path. The growing user base of 59,000 clinicians represents significant adoption in the physician community, driven by word-of-mouth among medical students and early-career physicians who use it as a reasoning aid.\n\nIn 2025, Glass Health competes in the AI clinical decision support market with UpToDate (Wolters Kluwer, the gold standard clinical reference), DynaMed (EBSCO Health), and emerging AI clinical reasoning platforms for physician decision support tools. The AI-powered CDS market is growing rapidly as large language models prove capable of medical reasoning at near-physician level on benchmarks. The 2025 strategy focuses on expanding to hospital systems (enterprise licensing for inpatient and outpatient clinical teams), building integrations with EHR systems for in-workflow access, and developing evidence validation processes that meet the requirements of clinical institutions adopting AI clinical tools.
AI quality assurance with insurance-backed warranties from Swiss Re and Greenlight Re; EU AI Act compliance assessments backed by YC and reinsurance partners for high-risk AI deployments.
Armilla AI is a third-party AI quality assurance and warranty company that evaluates AI models for organizations deploying AI in regulated or high-stakes contexts — assessing models against EU AI Act and NIST AI Risk Management Framework requirements for risks including bias, hallucination, robustness failures, and adversarial vulnerabilities, then providing performance guarantees backed by insurance coverage from reinsurers Swiss Re, Greenlight Re, and Chaucer. Founded in Toronto, Canada, Armilla raised $6.81 million total including a C$4.5 million seed round in February 2024 from Mistral Venture Partners, MS&AD Ventures, Y Combinator, and its reinsurance partners.\n\nArmilla's model is unique in the AI governance market — rather than just providing compliance reports, Armilla backs its assessments with insurance warranty products. An enterprise deploying a third-party AI model can purchase an Armilla warranty that pays out if the model performs differently than assessed (fails on bias, accuracy, or robustness metrics), transferring AI performance risk to insurance markets that can price and distribute it. This insurance mechanism creates financial accountability for AI quality claims that audit reports alone don't provide.\n\nIn 2025, Armilla competes in the AI governance, risk, and compliance market with Credo AI, Arthur AI, and AI audit firms for enterprise AI risk assessment and compliance tools. The EU AI Act, fully applicable by August 2025 for high-risk AI systems, is driving enterprise compliance urgency — companies deploying AI in hiring, credit scoring, healthcare, and other regulated contexts need third-party conformity assessments. Armilla's insurance-backed warranty differentiates its offering from pure advisory competitors. The reinsurer backing (Swiss Re, Greenlight Re, Chaucer) provides both capital credibility and distribution through insurance broker channels. The 2025 strategy focuses on growing EU AI Act compliance assessments and expanding the warranty product coverage to more AI deployment use cases.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.